Clinical Trial Update: Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759 [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating safety, tolerability, pharmacokinetics, and anti-tumor activity of AZD3759 in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD3759

Snippet

Sponsor: LYZZ Alpha Holding Ltd | Conditions: Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED